Tibotec to seek once-a-day Prezista regimen for experienced patients
This article was originally published in Scrip
Executive Summary
Tibotec (Johnson & Johnson) has shown that a once-daily regimen of its HIV protease inhibitor Prezista (darunavir) is non-inferior to a twice-daily dose in suppressing viral load in treatment-experienced HIV-1 infected patients in a Phase III study.